A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
Phase 2
Recruiting
- Conditions
- Obesity or Overweight
- Interventions
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 360
- Registration Number
- NCT06862791
- Locations
- 🇨🇳
Research Site, Kaohsiung, Taiwan
A Trial to Learn How Safe AZD9550 is in People With or Without Type 2 Diabetes Who Are Overweight or Obese
Phase 1
Active, not recruiting
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 88
- Registration Number
- NCT06151964
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT05848440
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath